Related references
Note: Only part of the references are listed.Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia:: An [18F]fallypride PET study
Gerhard Gruender et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Improvement of subjective well-being and enduring symptomatic remission, A 5-year follow-up of first episode schizophrenia
L. de Haan et al.
PHARMACOPSYCHIATRY (2008)
Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia:: A triple tracer PET study
David Mamo et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors:: A PET study in schizophrenia
Romina Mizrahi et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors:: Comparing aripiprazole to other antipsychotics in animal models
Sridhar Natesan et al.
NEUROPSYCHOPHARMACOLOGY (2006)
An automated method for the extraction of regional data from PET images
Pablo Rusjan et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2006)
Subjective experiences on antipsychotic medications: synthesis and conclusions
SR Marder
ACTA PSYCHIATRICA SCANDINAVICA (2005)
Subjective experiences during dopamine depletion
L De Haan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Neuroleptic dysphoria: towards a new synthesis
L Voruganti et al.
PSYCHOPHARMACOLOGY (2004)
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol:: A randomized, double-blind study
L de Haan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Effects of catecholamine depletion on D-2 receptor binding, mood, and attentiveness in humans: a replication study
NPLG Verhoeff et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2003)
Brain reward circuitry: Insights from unsensed incentives
RA Wise
NEURON (2002)
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
JM Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597):: A study using positron emission tomography and [11C]raclopride
F Yokoi et al.
NEUROPSYCHOPHARMACOLOGY (2002)
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
KD Burris et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Typical antipsychotic drugs -: D2 receptor occupancy and depressive symptoms in schizophrenia
RA Bressan et al.
SCHIZOPHRENIA RESEARCH (2002)
Subjective effects of AMPT-induced dopamine depletion in schizophrenia:: Correlation between dysphoric responses and striatal D2 binding ratios on SPECT imaging
L Voruganti et al.
NEUROPSYCHOPHARMACOLOGY (2001)
Imaging human mesolimbic dopamine transmission with positron emission tomography:: I.: Accuracy and precision of D2 receptor parameter measurements in ventral striatum
O Mawlawi et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2001)
A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects
NPLG Verhoeff et al.
NEUROPSYCHOPHARMACOLOGY (2001)
Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs
D Naber et al.
SCHIZOPHRENIA RESEARCH (2001)
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria
WC Drevets et al.
BIOLOGICAL PSYCHIATRY (2001)
Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone
L de Haan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans
M Fujita et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Share Paper
